ACLARION, INC. (ACON) Free cash flow
- Free cash flow · 12 months (USD): Value $-8.11M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -9680.86%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-8.11M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-8.09M − $22.86K ≈ $-8.11M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -9680.86% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-8.11M ÷ $83.77K × 100 ≈ -9680.86% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-8.09M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.88× | Operating cash flow / net income. Period ending 2026-06-30. $-8.09M ÷ $-9.20M ≈ 0.88× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -8.09M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 22.86K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -8.11M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 83.77K USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -9.20M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-8.11M | (m) | $-8.09M | $22.86K | (m) | $83.77K | (m) | $-9.20M | (m) | (m) | -9680.86% | 0.88× |
| 2026-03-31 | (m) | (m) | $-7.30M | (m) | (m) | $77.88K | (m) | $-8.05M | (m) | (m) | (m) | 0.91× |
| 2025-12-31 | $-7.19M | (m) | $-7.16M | $21.53K | (m) | $75.73K | (m) | $-7.23M | (m) | (m) | -9488.62% | 0.99× |
| 2025-09-30 | $-6.47M | (m) | $-6.46M | $12.92K | (m) | $67.48K | (m) | $-7.33M | (m) | (m) | -9591.37% | 0.88× |
| 2025-06-30 | $-6.36M | (m) | $-6.35M | $5.60K | (m) | $62.95K | (m) | $-6.99M | (m) | (m) | -10104.38% | 0.91× |
| 2025-03-31 | (m) | (m) | $-5.54M | (m) | (m) | $54.60K | (m) | $-6.63M | (m) | (m) | (m) | 0.84× |
| 2024-12-31 | $-5.28M | (m) | $-5.27M | $5.12K | (m) | $45.72K | (m) | $-6.99M | (m) | (m) | -11540.38% | 0.75× |
| 2024-09-30 | (m) | (m) | $-5.08M | (m) | (m) | $49.29K | (m) | $-6.27M | (m) | (m) | (m) | 0.81× |
| 2024-06-30 | (m) | (m) | $-4.98M | (m) | (m) | $53.95K | (m) | $-5.90M | (m) | (m) | (m) | 0.84× |
| 2024-03-31 | (m) | (m) | $-4.87M | (m) | (m) | $60.05K | (m) | $-6.13M | (m) | (m) | (m) | 0.80× |
| 2023-12-31 | (m) | (m) | $-3.65M | (m) | (m) | $75.40K | (m) | $-4.91M | (m) | (m) | (m) | 0.74× |
| 2023-09-30 | (m) | (m) | $-4.05M | (m) | (m) | $84.13K | (m) | $-4.59M | (m) | (m) | (m) | 0.88× |
| 2023-06-30 | (m) | (m) | $-4.19M | (m) | (m) | $83.28K | (m) | $-5.23M | (m) | (m) | (m) | 0.80× |
| 2023-03-31 | (m) | (m) | $-5.65M | (m) | (m) | $76.89K | (m) | $-7.32M | (m) | (m) | (m) | 0.77× |
| 2022-12-31 | (m) | (m) | $-5.31M | (m) | (m) | $60.44K | (m) | $-7.61M | (m) | (m) | (m) | 0.70× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $-2.40M | (m) | (m) | $60.29K | (m) | $-4.95M | (m) | (m) | (m) | 0.48× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |